Century Therapeutics, Inc. (IPSC) stock
IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.65+0.02 (+1.23%)
Close on Nov 13, 2026Market cap $298.77MP/E –Yield –
Century Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Century Therapeutics's profit margin for the twelve months ending Dec 31, 2025 was -8.8%. For fiscal 2025 it was -8.8%, against -1920.9% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -8.8% | +1912.1 |
| FY2024 | Dec 31, 2024 | -1920.9% | +4194.3 |
| FY2023 | Dec 31, 2023 | -6115.1% | −3596.7 |
| FY2022 | Dec 31, 2022 | -2518.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | 70.1% | +3352.2 |
| Q4 FY2024 | Dec 31, 2024 | -864.4% | +13836.3 |
| Q3 FY2024 | Sep 30, 2024 | -3947.7% | +18160.4 |
| Q2 FY2024 | Jun 30, 2024 | -4047.6% | +29579.7 |
| Q1 FY2024 | Mar 31, 2024 | -3282.1% | −1464.4 |
| Q4 FY2023 | Dec 31, 2023 | -14700.7% | −8619.7 |
| Q3 FY2023 | Sep 30, 2023 | -22108.1% | −20725.5 |
| Q2 FY2023 | Jun 30, 2023 | -33627.3% | −31407.5 |
| Q1 FY2023 | Mar 31, 2023 | -1817.7% | +1728.0 |
| Q4 FY2022 | Dec 31, 2022 | -6081.0% | – |
| Q3 FY2022 | Sep 30, 2022 | -1382.6% | – |
| Q2 FY2022 | Jun 30, 2022 | -2219.8% | – |
| Q1 FY2022 | Mar 31, 2022 | -3545.7% | – |
See a number that looks wrong?